The effect of intravenous gammaglobulin (IVGG) on the immunoregulatory abnormalities found during acute Kawasaki syndrome (KS) was studied in a randomized trial of IVGG plus aspirin (ASA) versus ASA alone. Before therapy, patients in each treatment group had increased numbers of circulating HLA-DR-bearing Leu 3+ helper T cells, a deficiency of Leu 2+ suppressor/cytotoxic T cells, and increased levels of spontaneous IgG and IgM synthesis by peripheral blood mononuclear cells. There were no significant differences (P > 0.1) between immunologic parameters measured on day 1 and day 4 in the ASAtreated group. In contrast, patients treated with ASA plus IVGG had by day 4 a highly significant decrease in HLA-Dr+ Leu 3+
Introduction
Kawasaki syndrome (KS)' is an acute febrile childhood disease of unknown etiology that is associated with the development of coronary artery aneurysms in 15-20% ofthe cases (1, 2) . Children with KS are usually placed on daily aspirin (ASA) as an antiinflammatory agent and to prevent platelet aggregation in blood vessels. There is however no definitive evidence that ASA therapy deminishes the frequency of coronary artery lesions in KS. Recently, it has been reported that administration of intravenous gammaglobulin (IVGG) in high doses during the acute phase of KS reduces the frequency of coronary artery aneurysms (3, 4) .
We have previously demonstrated that acute KS is characterized by immunoregulatory abnormalities of circulating lymphocytes. These abnormalities include a deficiency ofsuppressor! cytotoxic T cells, increased numbers of activated helper T cells, and increased B cell activation (5, 6) that is reflected by high levels of spontaneous immunoglobulin synthesis. Although multiple factors are likely to be involved in the pathogenesis of KS, the effect of high dose IVGG on the immunoregulatory imbalance observed during acute KS was of interest to us in attempting to unravel mechanisms by which IVGG prevents the development ofcoronary artery aneurysms in this disease. During an ongoing multicenter trial in the United States to study the effects of ASA alone versus ASA plus IVGG on the clinical outcome of KS, we have examined the effect of these agents on the immunoregulatory abnormalities in acute KS. The results ofthis study suggest that IVGG reverses the activation of T and B cells in vivo in acute KS.
Methods
Subjects. The study population consisted of 29 patients with acute KS who were seen at Children's Hospital between January, 1984 and March, 1985 . Eligibility for this study required that the patient meet the diagnostic criteria for KS and that they enter the study within 10 d ofonset of fever. The diagnostic criteria for KS were five or all six of the following signs: (a) fever of unknown etiology lasting for The two-color immunofluorescence experiments were analyzed with a fluorescence-activated cell sorter (FACS IV; Becton-Dickinson & Co.) as previously described (7) using 488-nm light (400 mW, argon laser) to excite both fluorochromes. Data were collected in a Consort-40 PDP/ 1 I computer system (Becton-Dickinson & Co.) for analysis ofboth singlecolor and two-color data. A total of 50,000 cells were analyzed in each experiment.
Measurement of spontaneous immunoglobulin (Ig) production. Spontaneous IgG and IgM synthesis was measured by culturing I X 106 PBMC/ml in RPMI 1640 medium containing 10% FCS (complete medium in the presence or absence of 100 ;Lg/ml cycloheximide. After 6 d at 370C in a 5% Co2 incubator, culture supernatants were assayed for IgG and IgM by a standard enzyme-linked immunosorbent assay (ELISA) method as previously described (8) . De novo IgG synthesis was calculated by determining the difference in IgG concentration between cycloheximide-treated cultures and cultures incubated in the absence ofthe protein synthesis inhibitor.
Assay of T cell supernatants for helper activity. T cell supernatants were generated by culturing T cells at 1 X 107/ml for 24 h in complete medium. Supernatants were then collected, filtered through a 0.45-,sm Millipore filter, and frozen at -20'C until tested. T cell supernatants were added at a 1 :1 dilution to cultures of normal B cells (1 X 106 cells/ ml) in complete medium in the presence or absence of 100 Mg/ml cycloheximide. After 6 d of culture, the de novo IgG content of B cell culture supernatant was determined with a standard ELISA method as previously described (8) .
Statistical evaluation. The two treatment groups were compared with regard to parameters at enrollment as well as to the change in these parameters between day I and day 4 of each treatment protocol using the Wilcoxon Rank Sum Test. We regarded a P value of: (a) < 0.05, as significant, (b) < 0.01, as highly significant, and (c) > 0.05 as not significant.
Results
Characteristics ofpatient study groups. Of the 29 patients with KS enrolled in this study, 14 were randomized to the ASA treatment group and 15 to the ASA plus IVGG treatment group. As shown in Table II , treatment groups were similar with respect to age distribution, sex, and duration of illness before entry into the study. Furthermore, patients enrolled into the two treatment groups did not differ significantly (P > 0.1) with regard to temperature or erythrocyte sedimentation rate.
Effects ofIVGG on T cell subsets in KS. The T cell subset distribution in patients with KS at the time of enrollment into the study is also summarized in Table II . There were no significant differences in the percentage of circulating Leu 4+ T, Leu 3+ Th, activated HLA-DR+ Leu 3+ Th or Leu 2+ Ts between the two treatment groups. PBMC from both groups demonstrated a significant decrease in the percentages of T cells in comparison with age-matched controls. This decrease in total T cells represented an absolute T cell lymphopenia because the mean value for the number of lymphocytes in the peripheral blood of patients with acute KS was lower than that obtained for the group ofage-matched controls (Table II) . The mean lymphocyte counts in patients at enrollment was similar in the two treatment groups. The decrease of circulating T cells in acute KS reflected a significant decrease in both Leu 2+ Ts and Leu 3+ Th. The decrease in Ts, however, was proportionately greater than that observed with Leu 3+ Th. As a result, KS patients entered into this study had an abnormally increased ratio of circulating Leu 3+ Th to Leu 2+ Ts. This ratio was 6.6±5.2 in the ASA-treated group and 8.0±3.3 in the IVGG group, compared with 2.4±0.4 in the control group (P < 0.01). More importantly, both groups had a highly significant elevation in the percentages of circulating activated HLA-DR+ Leu 3+ Th. "P < 0.01 when compared with normal controls.
'P <0.05 compared with normal controls. Fig. 1 summarizes the T cell subset distribution of PBMC from both treatment groups on day 1 and day 4 of the study. After 4 d of treatment, the IVGG plus ASA group underwent a greater increase in the percentage of Leu 4+ T cells, Leu 3+ Th, and Leu 2+ Ts (Fig. 1, A-C) than the ASA-treated group; these differences were not statistically significant (P = 0. 1) for changes in Leu 4+ T cells and Leu 3+ Th. Patients treated with IVGG plus ASA did, however, have a significantly greater increase in their percentages ofLeu 2+ Ts (P < 0.01) after the 4-d treatment period than did patients treated exclusively with ASA. The most dramatic change in T cell phenotype involved the percentage of circulating HLA-DR+ Leu 3+ Th before versus after treatment with IVGG plus ASA. Between the first and fourth treatment day, the percentage ofactivated HLA-DR+ Th in patients treated with IVGG plus ASA fell an average of 25.2%, as compared with a rise of 1.5% (P < 0.001) in children who received only aspirin (Fig. 1 D) .
Effect of IVGG on the production of T cell-derived B cell helperfactors. Activated Th from patients with acute KS have been previously demonstrated to produce soluble helper factors that induce B cells to secrete IgG (6) . To determine whether the decrease in HLA-DR+ Th was associated with a functional change of helper cells, we examined the capacity ofthe patient's T cells to spontaneously release B cell helper factors on day I and day 4 of each treatment. Supernatants from 24-h cultures offreshly isolated unstimulated T cells derived from four patients in the ASA-treated group, five patients in the ASA plus IVGGtreated group and five normal controls were tested for their capacity to induce IgG production in cultures of purified B cells from a single normal donor. Fig. 2 shows that T cell supernatants derived from the KS patients before treatment induced significantly more (P < 0.01) IgG synthesis than supernatants ofnormal T cells. There was no significant difference between either treatment group in the capacity oftheir T cell supernatants to induce IgG production on day 1 of the protocol. ability to induce IgG production in the same B cell donor. Between day 1 and day 4 of the study, the decline in capacity of T cells to secrete B cell helper factors was significantly greater in the IVGG plus ASA-treated group than in the ASA-treated group (P < 0.001). Effect ofIVGG on spontaneous immunoglobulin synthesis.
In this series of experiments, we examined the level of spontaneous IgG and IgM production by PBMC obtained on day 1 and day 4 of each treatment protocol. Before treatment, spontaneous IgG and IgM synthesis in acute KS patients was significantly elevated (Fig. 3) . There was no significant difference between the pretreatment spontaneous IgG and IgM synthesis of the acute KS patients assigned to the ASA regimen versus those assigned to the ASA plus IVGG regimen. After treatment with ASA plus IVGG there was a highly significant decrease in spontaneous immunoglobulin synthesis as compared with the group receiving ASA treatment alone. Between enrollment and treatment day 4, PBMC from patients treated with ASA plus IVGG had a mean decrease in IgG synthesis of 853±142 ng/ml (P < 0.001), and a mean decrease in IgM synthesis of 554±56 ng/ml (P < 0.001). In contrast, after 4 d oftreatment with ASA alone, PBMC secreted slightly higher levels of IgG (mean increase, 85±78 ng/ml) and IgM (mean increase, 28±24 ng/ml) than PBMC obtained at enrollment.
TREATMENT PROTOCOL DAY Table I .
Discussion
In the present study we The current investigation also documented an absolute T lymphopenia during the first 10 d after onset of KS. The T lymphopenia was reflected in a loss of helper T cells and a disproportionately greater loss of suppressor/cytotoxic T cells. Infusion of high dose IVGG increased the total T cell numbers and helper T cell numbers to normal levels. Although the percent suppressor/cytotoxic T cells after infusion of IVGG increased significantly when compared with the ASA-treated group, they remained lower than those of age-matched controls.
The mechanisms by which IVGG reverses the immunoregulatory abnormalities in KS are unknown. Potential mechanisms include: (a) feedback inhibition of antibody-producing system; (b) increased antigen clearance of the infectious agent or toxin mediating KS; and (c) nonspecific immunologic blockade via the infusion of anti-HLA-DR antibodies in pooled IVGG or binding of intact IgG to Fc receptors of the lymphoid and/or reticuloendothelial cell system.
The optimal production of immunoglobulin requires a favorable balance between helper T cells and suppressor T cells. (24) . These findings suggest that T cell activation in acute KS could be a predisposing factor to vasculitis. Based on the above observations, we postulate that IVGG may prevent the development of coronary artery aneurysms in KS by interrupting the immunologic cascade that results in blood vessel injury at several sites. First, by reducing the level of T cell activation and the secretion oflymphokines, IVGG would cause a reduction in the expression of new surface antigens on vascular endothelium. Second, by inhibiting antibody production, IVGG would inhibit the formation of antibodies to neoantigens on endothelial cells. Finally, by binding to Fc receptors of reticuloendothelial cells, IVGG would reduce the binding of immune complexes to such cells. These possibilities are currently being investigated in our laboratory.
